Actively Recruiting
Interstitial Lung Disease: A Study From Infancy to Elderly Including Relatives
Led by Institut National de la Santé Et de la Recherche Médicale, France · Updated on 2026-02-12
3000
Participants Needed
1
Research Sites
478 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The concerned patients are children and adults suffering from idiopathic interstitial pneumonias, other chronic fibrosing interstitial pneumonias with a progressive phenotype, and interstitial pneumonia associated with Scleroderma and related cases of patients carrying a mutation on one of the telomere-associated genes. This is a national, observational, longitudinal, multicenter study that will be conducted retrospectively and prospectively. It aims to collect consistent and comparable clinical data for patients and their relatives, whether they carry a mutation or not, affected by diffuse idiopathic interstitial pneumopathy. The expected duration of the study, including data analysis, is approximately 10 years (5 years for participant enrollment and 5 years of follow-up, in addition to the steps for data management and statistical analyses). Each participating center will inform every participant by providing an information sheet, and their written consent will be obtained before including them in the study and commencing data collection. Prospective medical data will be collected at 6 months to 1 year after enrollment and then at least once per year for patients up to 5 years and 5 years for their relatives. Participants will complete a self-questionnaire during their regular follow-up consultations or by accessing a secure interface.
CONDITIONS
Official Title
Interstitial Lung Disease: A Study From Infancy to Elderly Including Relatives
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of idiopathic interstitial pneumonia based on clinical, radiological, or functional criteria
- Confirmed diagnosis of progressive fibrotic interstitial lung disease with at least 10% fibrosis on CT scan and disease worsening not due to other causes
- Evidence of disease progression over 24 months with specific declines in lung function or worsening symptoms
- Confirmed diagnosis of Systemic Sclerosis-associated Interstitial Lung Disease with disease involving at least 10% of the lungs on high-resolution CT scan
- First-degree relatives of patients with mutations in telomere-associated genes such as TERT, TERC, RTEL1, TINF2, DKC1, and PARN
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
RaDiCo-ILD2
Paris, Île-de-France Region, France, 75012
Actively Recruiting
Research Team
V
Vincent Cottin, Pr
CONTACT
A
Annick Clement, Pr
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here